The Insider Report: The Dip Was Bought Before the Holidays
Market Overview As I shared in last week’s report, the dip buying opportunity in markets was capitalized upon…
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
Guggenheim starts coverage on Chinook Therapeutics Inc (NASDAQ:KDNY) with a Buy rating and a $43 price target, being ‘bullish’ on the immunoglobulin…
Reported Late Tuesday Feb. 28, Travere Therapeutics Announces Pricing Of $200M Upsized Public Offering Of 8.275M Shares Of Common Stock At A Price Of $21/Share And 1.25M Pre-Funded Warrants
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a price to the public of $21.00 per share and, in lieu of
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.
Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $46
Piper Sandler analyst Do Kim maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $42 to $46.
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
The FDA granted accelerated approval to Travere Therapeutics Inc’s (NASDAQ:TVTX) Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk…
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Raises Price Target to $40
HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $36 to $40.
Travere Therapeutics FILSPARI New Drug Application For Type 1 – New Molecular Entity Was Approved On 02/17/2023
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216403
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $36 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $36 price target.